- Home
- ADN vs APRE Comparison
ADN vs APRE Comparison
Compare ADN & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADN
- APRE
- Stock Information
- Founded
- ADN 2006
- APRE 2006
- Country
- ADN United States
- APRE United States
- Employees
- ADN N/A
- APRE N/A
- Industry
- ADN Power Generation
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ADN Utilities
- APRE Health Care
- Exchange
- ADN Nasdaq
- APRE Nasdaq
- Market Cap
- ADN 7.5M
- APRE 8.4M
- IPO Year
- ADN N/A
- APRE 2019
- Fundamental
- Price
- ADN $1.90
- APRE $1.62
- Analyst Decision
- ADN
- APRE Strong Buy
- Analyst Count
- ADN 0
- APRE 2
- Target Price
- ADN N/A
- APRE $15.50
- AVG Volume (30 Days)
- ADN 23.1K
- APRE 29.8K
- Earning Date
- ADN 12-27-2024
- APRE 05-13-2025
- Dividend Yield
- ADN N/A
- APRE N/A
- EPS Growth
- ADN N/A
- APRE N/A
- EPS
- ADN N/A
- APRE N/A
- Revenue
- ADN $8,157,000.00
- APRE $1,502,581.00
- Revenue This Year
- ADN $2,232.99
- APRE N/A
- Revenue Next Year
- ADN $91.56
- APRE N/A
- P/E Ratio
- ADN N/A
- APRE N/A
- Revenue Growth
- ADN 274.35
- APRE 157.63
- 52 Week Low
- ADN $1.71
- APRE $1.41
- 52 Week High
- ADN $8.79
- APRE $5.90
- Technical
- Relative Strength Index (RSI)
- ADN 21.25
- APRE 36.93
- Support Level
- ADN $2.49
- APRE $1.41
- Resistance Level
- ADN $2.84
- APRE $1.59
- Average True Range (ATR)
- ADN 0.34
- APRE 0.11
- MACD
- ADN -0.08
- APRE 0.03
- Stochastic Oscillator
- ADN 0.00
- APRE 48.04
About ADN Advent Technologies Holdings Inc.
Advent Technologies Holdings Inc is an innovation-driven company in the fuel cell and hydrogen technology space. The company develops, manufactures, and assembles complete fuel cell systems and the critical components that determine the performance of hydrogen fuel cells and other energy systems. It serves automotive; aviation and power generation industries. It generates revenue from the sale of fuel cell systems and the sale of MEAs, membranes, and electrodes for specific applications in the fuel cell and energy storage (flow battery) markets.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.